Skip to content
Mercury Laboratories logo

Mercury Laboratories

538964 BSE
Price unavailable

Mercury Laboratories (MERCURYLAB) share price was ₹749.95 at the 27 Oct 2026 close; market capitalisation ₹89.99 Cr; P/E (TTM) 21.58; sector Healthcare. The share price fell 10.8% over the year to 27 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 12.0% year on year to ₹15.96 Cr and net profit was ₹0.30 Cr, against ₹0.97 Cr a year earlier (compared with Jun 2025). Promoters held 73.66% of Mercury Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 56/100 (Good) as of 28 Oct 2026.

Close 27 Oct 2026 ₹749.95 −125.05 −14.29% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹89.99 Cr
P/E (TTM)
21.58
EBITDA
₹11.00 Cr
Return on Equity
8.32%
Debt to Equity
0.15
Book Value
₹483.97
EPS (TTM)
₹34.75
52W High
₹928.50
52W Low
₹620.55

Price-based figures as of 27 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,767.5035.064,24,082 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,607.8072.341,75,266 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.30108.071,18,182 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.8026.301,17,885 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,339.3034.691,11,789 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.2032.711,10,289 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Mercury Laboratories (this company)
—21.5890 Cr1.550.47%8.32%10.66%76 Cr4 Cr
Median 8 companies₹1,767.5034.881,18,034 Cr4.710.54%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

56 Good
Overall score

Data confidence 100/100

Category scores

Quality Good 65
Returns, margins, earnings quality 22% weight
Valuation Good 58
Cheap vs sector & own history 24% weight
Growth Poor 32
Sales & profit trajectory 9% weight
Financial Health Strong 72
Solvency, leverage, coverage 9% weight
Momentum Average 51
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

2
  • The company has delivered a poor sales growth of 2.05% over past five years.
  • Company has a low return on equity of 8.83% over last 3 years.

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

Bearish

Bearish
10
Neutral
6
Bullish
3

Moving Averages

Bearish

Bearish
8
Neutral
0
Bullish
2

Growth Rate

Revenue Growth
2.23% higher than 3Y

change over 1 year

Net Income Growth
54.84% higher than 3Y

change over 1 year

Cash Flow Change
-12.76%

change over 1 year

EBITDA Margin Change
33.08%

change over 1 year Operating margin 7.46% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
18.32
22.76
17.11
17.37
16.68
18.19
19.57
20.66
18.14
19.01
18.35
20.44
15.96
Expenses
16.66
20.28
14.88
14.71
15.07
16.88
17.59
18.53
15.78
16.88
15.83
18.4
14.77
Operating Profit
1.66
2.48
2.23
2.66
1.61
1.31
1.98
2.13
2.36
2.13
2.52
2.04
1.19
OPM %
9.06%
10.9%
13.03%
15.31%
9.65%
7.2%
10.12%
10.31%
13.01%
11.2%
13.73%
9.98%
7.46%
Other Income
0.15
0.36
0.18
0.41
0.15
0.21
0.53
0.18
0.18
0.79
-0.08
0.67
0.05
Interest
0.08
0.11
0.1
0.1
0.14
0.15
0.13
0.13
0.15
0.13
0.14
0.13
0.12
Depreciation
0.68
0.71
0.72
0.72
0.7
0.71
0.74
0.73
0.84
0.86
0.87
0.84
0.73
PBT
1.05
2.02
1.59
2.25
0.92
0.66
1.64
1.45
1.55
1.93
1.43
1.74
0.39
Tax %
5.71%
25.74%
22.01%
15.11%
63.04%
22.73%
27.44%
23.45%
37.42%
14.51%
30.77%
29.31%
23.08%
Net Profit
1
1.51
1.24
1.91
0.34
0.5
1.19
1.11
0.97
1.64
1
1.23
0.3
EPS (₹)
8.33
12.58
10.33
15.92
2.83
4.17
9.92
9.25
8.08
13.67
8.33
10.25
2.5
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
41.19
47.51
48.02
51.86
55.52
57.27
68.6
57.92
75.33
75.56
75.1
75.94
73.76
Expenses
35.4
41.04
41.3
47.44
49.79
51.1
59.01
50.92
66.73
66.53
68.08
66.91
65.88
Operating Profit
5.79
6.47
6.72
4.42
5.73
6.17
9.59
7
8.6
9.03
7.02
9.03
7.88
OPM %
14.06%
13.62%
13.99%
8.52%
10.32%
10.77%
13.98%
12.09%
11.42%
11.95%
9.35%
11.89%
10.68%
Other Income
1.12
0.78
0.35
0.42
1.04
0.85
0.88
0.94
1.69
1.09
1.07
1.57
1.43
Interest
1.12
1.13
0.89
0.91
1.09
0.82
0.64
0.45
0.36
0.38
0.55
0.54
0.52
Depreciation
1.18
1.18
1.29
1.47
1.63
1.87
1.92
2.45
2.48
2.82
2.88
3.42
3.3
PBT
4.61
4.94
4.89
2.46
4.05
4.33
7.91
5.04
7.45
6.92
4.66
6.64
5.49
Tax %
27.98%
20.45%
44.79%
17.89%
29.88%
25.4%
32.49%
29.17%
24.97%
18.35%
32.62%
27.11%
—
Net Profit
3.31
3.92
2.7
2.01
2.84
3.23
5.34
3.56
5.58
5.65
3.14
4.83
4.17
EPS (₹)
27.58
32.67
22.5
16.75
23.67
26.92
44.5
29.67
46.5
47.08
26.17
40.25
34.75
Div. Payout %
5.44%
4.59%
6.67%
8.96%
6.34%
7.43%
7.87%
11.8%
7.53%
7.43%
13.38%
8.7%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
1.2
1.2
1.2
1.2
1.2
1.2
1.2
1.2
1.2
1.2
1.2
1.2
Reserves
16.94
20.65
23.27
25.15
27.77
30.78
35.69
39.11
44.43
49.64
52.37
56.88
Borrowings
8.88
7.37
7.44
9.76
9.56
7.19
7.1
5.99
5.83
5.55
5.45
8.43
Other Liabilities
15.5
17.3
19.23
15.59
18.76
17.13
21.38
16.14
12.7
11.56
15.21
12.57
Total Liabilities
42.52
46.52
51.14
51.7
57.29
56.3
65.37
62.44
64.16
67.95
74.23
79.08
Fixed Assets
19.48
18.57
18.39
20.78
24.39
23.66
26.36
25.82
24.26
24.03
24.64
23.88
CWIP
0
0
0.4
0.24
0
0
0
0
0.13
3.82
9.32
9.82
Investments
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Other Assets
23.03
27.94
32.34
30.67
32.89
32.63
39
36.61
39.76
40.09
40.26
45.37
Total Assets
42.52
46.52
51.14
51.7
57.29
56.3
65.37
62.44
64.16
67.95
74.23
79.08
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
3.49
-0.1
1.92
4.97
5.22
5.49
8.21
5.19
2.45
8.23
4.86
4.24
Investing
-1.54
-0.28
-1.5
-3.68
-4.99
-1.14
-4.62
-1.89
-1.06
-6.27
-9.04
-3.17
Financing
-2.12
0.47
-0.25
1.07
-2.54
-3.33
-1.24
-1.23
-1.01
-1.04
-1.85
2.91
Net Cash Flow
-0.18
0.09
0.17
2.36
-2.31
1.02
2.36
2.07
0.38
0.91
-6.03
3.99
Free Cash Flow
1.95
-0.38
0.42
1.29
0.23
4.35
3.59
3.3
1.39
1.96
-4.18
1.07
CFO/OP
82
20
45
129
109
109
100
101
41
105
103
61
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
108
103
133
104
127
116
120
105
104
106
125
124
Inventory Days
93.92
116
137
120
93.95
78.44
60.42
105
82.82
75.88
92.47
89.34
Days Payable
159
136
187
139
162
120
138
106
76.58
63.3
126
78.42
Cash Conversion Cycle
42.37
82.19
83.99
84.75
59.05
74.04
42.41
104
110
118
91.5
135
Working Capital Days
9.22
46.86
103
90.58
88.75
88.78
75.02
79.02
87.02
91.64
107
130
ROCE %
21.35%
21.59%
18.91%
9.82%
13.77%
13.26%
20.56%
11.83%
16.04%
13.41%
8.94%
12.06%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Mercury Laboratories insights

64 extracted metrics + investor summaries across FY05–FY27.

Shareholding Pattern

Promot.73.66%Others9.75%Public16.59%As ofSep 2026

Documents

Frequently Asked Questions about Mercury Laboratories

What does Mercury Laboratories Ltd do?
Incorporated in 1962, Mercury Laboratories Ltd manufactures and exports Pharmaceutical items of gyno and pediatrics.[1]
Where is Mercury Laboratories Ltd (MERCURYLAB) listed?
Mercury Laboratories Ltd trades under code 538964 on the BSE.
Which sector does Mercury Laboratories Ltd belong to?
Mercury Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Mercury Laboratories Ltd?
Mercury Laboratories Ltd has a market capitalisation of ₹89.99 Cr as of 27 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Mercury Laboratories Ltd?
Mercury Laboratories Ltd trades at a PE ratio of 21.58 as of 27 Oct 2026, on earnings per share of ₹34.75, against a book value of ₹483.97 per share.
What is the 52-week high and low of Mercury Laboratories Ltd?
Over the last 52 weeks Mercury Laboratories Ltd has traded between ₹620.55 and ₹928.5 as of 27 Oct 2026.
Does Mercury Laboratories Ltd pay dividends?
Mercury Laboratories Ltd has a dividend yield of 0.47%.
What is the Return on Equity (ROE) of Mercury Laboratories Ltd?
Mercury Laboratories Ltd reported a return on equity of 8.32%. Its debt-to-equity ratio is 0.15.

Company Information

Incorporated in 1962, Mercury Laboratories Ltd manufactures and exports Pharmaceutical items of gyno and pediatrics.[1]

Website mercurylabs.com
Listed 2015-02-26
Face Value ₹ 10
Shares Outstanding 12,00,000

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/538964.md for Mercury Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month